Sarah Turpin-Nolan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarah Turpin-Nolan has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Matthew J. Watt
Biology of Lipid Metabolism Laboratory, Department of Physiology (A.J.H., S.M.T., A.J.M., M.J.W.), Monash University, Clayton, Victoria, 3800, Australia
3 shared publications- Andrew J. Hoy
School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Camperdown Australia
2 shared publications - Bruce E. Kemp
St. Vincent's Institute of Medical Research and Department of Medicine, University of Melbourne & Mary MacKillop Institute for Health Research, Australian Catholic University Fitzroy, Fitzroy, Victoria, Australia
2 shared publications - Ian Andrew Darby
RMIT University
2 shared publications Mark A. Febbraio
Cellular & Molecular Metabolism Laboratory (C.R.B., M.A.F.), Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, 3004, Australia
2 shared publications- Mark Anthony Febbraio
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia
2 shared publications
Latest Publications
- Open Access
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx3794
The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice
The chimeric cytokine IC7Fc conveys the metabolic signaling properties of the glycoprotein 130 receptor cytokines interleukin-6 and ciliary neurotrophic factor via membrane-bound signaling. IC7Fc was previously shown to slow the progression of type 2 diabetes mellitus, and here, we demonstrate its effect on atherosclerotic development. In APOE*3-Leiden.CETP mice, an atherosclerosis-prone model with a humanized lipoprotein metabolism, IC7Fc markedly lowered plasma triglyceride and total cholesterol levels. This was mechanistically explained by an inhibition of de novo lipogenesis in the liver, increased synthesis of bile acids from cholesterol, and down-regulated apolipoprotein B synthesis, which resulted in decreased cholesterol secretion in very low–density lipoprotein particles. As a consequence, IC7Fc treatment considerably reduced atherosclerotic lesion formation and vascular inflammation compared with current antihyperlipidemic therapy. In conclusion, IC7Fc is a promising pharmacological treatment for cardiometabolic diseases targeting hyperlipidemia and inflammation.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx3794
Open AccessThe designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice
The chimeric cytokine IC7Fc conveys the metabolic signaling properties of the glycoprotein 130 receptor cytokines interleukin-6 and ciliary neurotrophic factor via membrane-bound signaling. IC7Fc was previously shown to slow the progression of type 2 diabetes mellitus, and here, we demonstrate its effect on atherosclerotic development. In APOE*3-Leiden.CETP mice, an atherosclerosis-prone model with a humanized lipoprotein metabolism, IC7Fc markedly lowered plasma triglyceride and total cholesterol levels. This was mechanistically explained by an inhibition of de novo lipogenesis in the liver, increased synthesis of bile acids from cholesterol, and down-regulated apolipoprotein B synthesis, which resulted in decreased cholesterol secretion in very low–density lipoprotein particles. As a consequence, IC7Fc treatment considerably reduced atherosclerotic lesion formation and vascular inflammation compared with current antihyperlipidemic therapy. In conclusion, IC7Fc is a promising pharmacological treatment for cardiometabolic diseases targeting hyperlipidemia and inflammation.
- Open Access
- 28 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2097
Investigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats
Background/Objectives: Lower urinary tract symptoms (LUTS), such as frequency, urgency, nocturia, and urge incontinence, are commonly linked to overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Oxytocin receptor (OXTR) upregulation has been proposed to enhance bladder and prostate contractility, while obesity is a recognized risk factor for LUTS, OAB, and BPH. This study aimed to investigate whether the OXTR antagonist atosiban attenuates spontaneous and oxytocin-induced contractions in bladder and prostate tissues from obese and non-obese rats. Methods: Bladder and prostate tissues were obtained from obese and non-obese rats and studied in in vitro organ bath preparations. The effects of atosiban (1 µM and 10 µM) on spontaneous contractility and oxytocin-induced responses were examined. Immunohistochemistry was performed to evaluate OXTR expression in the bladder. Results: Atosiban significantly reduced spontaneous contractions in the bladder (p < 0.0001 in obese; p < 0.01 in non-obese) and prostate (p < 0.01 in obese; p < 0.0001 in non-obese). Oxytocin-induced bladder contractions were significantly increased in obese rats but were attenuated by atosiban at 10 µM (p < 0.05), an effect absent in non-obese rats. Immunohistochemical analysis confirmed elevated OXTR expression in both epithelial and stromal compartments of the bladder in obese rats (p < 0.05). Conclusions: These findings indicate that oxytocin contributes to bladder and prostate hypercontractility, particularly in obesity. Targeting OXTR with atosiban may represent a novel therapeutic strategy for the management of LUTS, OAB, and BPH.
- 28 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2097
Open AccessInvestigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats
Background/Objectives: Lower urinary tract symptoms (LUTS), such as frequency, urgency, nocturia, and urge incontinence, are commonly linked to overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Oxytocin receptor (OXTR) upregulation has been proposed to enhance bladder and prostate contractility, while obesity is a recognized risk factor for LUTS, OAB, and BPH. This study aimed to investigate whether the OXTR antagonist atosiban attenuates spontaneous and oxytocin-induced contractions in bladder and prostate tissues from obese and non-obese rats. Methods: Bladder and prostate tissues were obtained from obese and non-obese rats and studied in in vitro organ bath preparations. The effects of atosiban (1 µM and 10 µM) on spontaneous contractility and oxytocin-induced responses were examined. Immunohistochemistry was performed to evaluate OXTR expression in the bladder. Results: Atosiban significantly reduced spontaneous contractions in the bladder (p < 0.0001 in obese; p < 0.01 in non-obese) and prostate (p < 0.01 in obese; p < 0.0001 in non-obese). Oxytocin-induced bladder contractions were significantly increased in obese rats but were attenuated by atosiban at 10 µM (p < 0.05), an effect absent in non-obese rats. Immunohistochemical analysis confirmed elevated OXTR expression in both epithelial and stromal compartments of the bladder in obese rats (p < 0.05). Conclusions: These findings indicate that oxytocin contributes to bladder and prostate hypercontractility, particularly in obesity. Targeting OXTR with atosiban may represent a novel therapeutic strategy for the management of LUTS, OAB, and BPH.
- Open Access
- 23 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (34) , eadp2254
High-fat feeding drives the intestinal production and assembly of C 16:0 ceramides in chylomicrons
Consumption of a diet rich in saturated fat increases lipid absorption from the intestine, assembly into chylomicrons, and delivery to metabolic tissues via the lymphatic and circulatory systems. Accumulation of ceramide lipids, composed of sphingosine and a fatty acid, in metabolic tissues contributes to the pathogenesis of cardiovascular diseases, type 2 diabetes mellitus and cancer. Using a mesenteric lymph duct cannulated rat model, we showed that ceramides are generated by the intestine and assembled into chylomicrons, which are transported via the mesenteric lymphatic system. A lipidomic screen of intestinal-derived chylomicrons identified a diverse range of fatty acid, sphingolipid, and glycerolipid species that have not been previously detected in chylomicrons, including the metabolically deleterious C 16:0 ceramide that increased in response to high-fat feeding in rats and human high-lipid meal replacement enteral feeding. In conclusion, high-fat feeding increases the export of intestinal-derived C 16:0 ceramide in chylomicrons, identifying a potentially unknown mechanism through which ceramides are transported systemically to contribute to metabolic dysfunction.
- 23 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (34) , eadp2254
Open AccessHigh-fat feeding drives the intestinal production and assembly of C 16:0 ceramides in chylomicrons
Consumption of a diet rich in saturated fat increases lipid absorption from the intestine, assembly into chylomicrons, and delivery to metabolic tissues via the lymphatic and circulatory systems. Accumulation of ceramide lipids, composed of sphingosine and a fatty acid, in metabolic tissues contributes to the pathogenesis of cardiovascular diseases, type 2 diabetes mellitus and cancer. Using a mesenteric lymph duct cannulated rat model, we showed that ceramides are generated by the intestine and assembled into chylomicrons, which are transported via the mesenteric lymphatic system. A lipidomic screen of intestinal-derived chylomicrons identified a diverse range of fatty acid, sphingolipid, and glycerolipid species that have not been previously detected in chylomicrons, including the metabolically deleterious C 16:0 ceramide that increased in response to high-fat feeding in rats and human high-lipid meal replacement enteral feeding. In conclusion, high-fat feeding increases the export of intestinal-derived C 16:0 ceramide in chylomicrons, identifying a potentially unknown mechanism through which ceramides are transported systemically to contribute to metabolic dysfunction.
- Open Access
- 27 July 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomarkers are implicated in metabolic disease and the circulating levels of these biomarkers are used in clinical settings to predict and monitor disease severity. There is convincing evidence that specific circulating ceramide species can be used as biological predictors and markers of cardiovascular disease, atherosclerosis and type 2 diabetes mellitus. Here, we review the existing literature that investigated sphingolipids as biomarkers for metabolic disease prediction. What are the advantages and disadvantages? Are circulating ceramides predominantly produced in the liver? Will hepatic sphingolipid inhibitors be able to completely prevent and treat metabolic disease? As sphingolipids are being employed as biomarkers and potential metabolic disease treatments, we explore what is currently known and what still needs to be discovered.
- 27 July 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Open AccessCirculating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomarkers are implicated in metabolic disease and the circulating levels of these biomarkers are used in clinical settings to predict and monitor disease severity. There is convincing evidence that specific circulating ceramide species can be used as biological predictors and markers of cardiovascular disease, atherosclerosis and type 2 diabetes mellitus. Here, we review the existing literature that investigated sphingolipids as biomarkers for metabolic disease prediction. What are the advantages and disadvantages? Are circulating ceramides predominantly produced in the liver? Will hepatic sphingolipid inhibitors be able to completely prevent and treat metabolic disease? As sphingolipids are being employed as biomarkers and potential metabolic disease treatments, we explore what is currently known and what still needs to be discovered.
- Top Cited PapersOpen Access
- 1 January 2019
- Published by Elsevier in Cell Reports
- Vol. 26 (1) , 1-10.e7
CerS1-Derived C18:0 Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance
- 1 January 2019
- Published by Elsevier in Cell Reports
- Vol. 26 (1) , 1-10.e7
Top Cited PapersOpen AccessCerS1-Derived C18:0 Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Ceramide synthase 6 inhibition as a novel therapeutic approach for obesity and type 2 diabetes
Excess consumption of saturated fatty acids may lead to an increased production of ceramides that contribute to development of insulin resistance and type 2 diabetes. Substantial research demonstrated that inhibition of ceramide biosynthesis ameliorates atherosclerosis, hepatic steatosis, insulin resistance and obesity. However, as ceramides and their sphingolipid products are involved in multiple fundamental cellular processes, concerns exist about possible risks or adverse effects resulting from overall inhibition of sphingolipid synthesis for treatment of chronic diseases. Therefore, the inhibition of specific ceramide species represents a new strategy for pharmaceutical intervention. Recent research demonstrated that specifically CerS6 mediated C16 ceramide synthesis plays a key role in the development of obesity mediated insulin resistance. In the current study, we investigated the effects of specifically knocking-down CerS6 in ob/ob mice using CerS6 anti-sense oligonucleotides (ASO). In this animal model, CerS6 expression is significantly higher vs. lean control mice (~2 fold in the liver and BAT) which correlates with a 4-fold increase of C16 ceramide in the plasma and a 2-fold increase in the liver. CerS6 ASO treatment led to selective and significant ~80% knockdown of the CerS6 expression in the liver and correlated with a significant 50% reduction of C16 ceramide in the liver and plasma compared to control ASO-treated ob/ob mice. CerS6 knockdown protected against body weight gain and was associated with a significant reduction in fat mass and blood glucose levels. Moreover, insulin resistance was significantly improved by ASO treatment as evidenced by oral glucose tolerance and insulin tolerance tests (~50% reduction in AUC during oGTT). In conclusion, CerS6 dependent C16 ceramide synthesis represents a distinct sphingolipid species, which contributes to the development of obesity and insulin resistance and therefore may represent a unique and attractive novel target to treat obesity and type 2 diabetes.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Ceramide synthase 6 inhibition as a novel therapeutic approach for obesity and type 2 diabetes
Excess consumption of saturated fatty acids may lead to an increased production of ceramides that contribute to development of insulin resistance and type 2 diabetes. Substantial research demonstrated that inhibition of ceramide biosynthesis ameliorates atherosclerosis, hepatic steatosis, insulin resistance and obesity. However, as ceramides and their sphingolipid products are involved in multiple fundamental cellular processes, concerns exist about possible risks or adverse effects resulting from overall inhibition of sphingolipid synthesis for treatment of chronic diseases. Therefore, the inhibition of specific ceramide species represents a new strategy for pharmaceutical intervention. Recent research demonstrated that specifically CerS6 mediated C16 ceramide synthesis plays a key role in the development of obesity mediated insulin resistance. In the current study, we investigated the effects of specifically knocking-down CerS6 in ob/ob mice using CerS6 anti-sense oligonucleotides (ASO). In this animal model, CerS6 expression is significantly higher vs. lean control mice (~2 fold in the liver and BAT) which correlates with a 4-fold increase of C16 ceramide in the plasma and a 2-fold increase in the liver. CerS6 ASO treatment led to selective and significant ~80% knockdown of the CerS6 expression in the liver and correlated with a significant 50% reduction of C16 ceramide in the liver and plasma compared to control ASO-treated ob/ob mice. CerS6 knockdown protected against body weight gain and was associated with a significant reduction in fat mass and blood glucose levels. Moreover, insulin resistance was significantly improved by ASO treatment as evidenced by oral glucose tolerance and insulin tolerance tests (~50% reduction in AUC during oGTT). In conclusion, CerS6 dependent C16 ceramide synthesis represents a distinct sphingolipid species, which contributes to the development of obesity and insulin resistance and therefore may represent a unique and attractive novel target to treat obesity and type 2 diabetes.
- Top Cited Papers
- 1 October 2014
- Published by Elsevier in Cell Metabolism
- Vol. 20 (4) , 678-686
Obesity-Induced CerS6-Dependent C16:0 Ceramide Production Promotes Weight Gain and Glucose Intolerance
- 1 October 2014
- Published by Elsevier in Cell Metabolism
- Vol. 20 (4) , 678-686
Top Cited PapersObesity-Induced CerS6-Dependent C16:0 Ceramide Production Promotes Weight Gain and Glucose Intolerance
- 1 January 2011
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (1) , 48-58
Adipose Triglyceride Lipase-Null Mice Are Resistant to High-Fat Diet–Induced Insulin Resistance Despite Reduced Energy Expenditure and Ectopic Lipid Accumulation
Adipose triglyceride lipase (ATGL) null (−/−) mice store vast amounts of triacylglycerol in key glucoregulatory tissues yet exhibit enhanced insulin sensitivity and glucose tolerance. The mechanisms underpinning these divergent observations are unknown but may relate to the reduced availability of circulating fatty acids. The aim of this study was to determine whether the enhancements in insulin stimulated glucose metabolism in ATGL−/− mice persist when challenged with a high-fat diet. ATGL−/− mice fed a low-fat diet exhibit improved whole-body insulin sensitivity and glucose tolerance compared with wild-type mice. Wild-type mice became hyperlipidemic and insulin-resistant when challenged with a high-fat diet (HFD, 60% fat) for 4 wk. ATGL−/− mice fed a HFD had elevated circulating fatty acids but had reduced fasting glycemia compared to pre–high-fat diet levels and were refractory to glucose intolerance and insulin resistance. This protection from high-fat diet–induced metabolic perturbations was associated with a preference for fatty acid utilization but reduced energy expenditure and no change in markers of mitochondrial capacity or density. The protection from high-fat diet–induced insulin resistance in ATGL−/− mice was due to increased cardiac and liver insulin-stimulated glucose clearance despite increased lipid content in these tissues. Additionally, there was no difference in skeletal muscle insulin-stimulated glucose disposal, but there was a reduction observed in brown adipose tissue. Overall, these results show that ATGL−/− mice are protected from HFD-induced insulin resistance and reveal a tissue specific disparity between lipid accumulation and insulin sensitivity.
- 1 January 2011
- Published by The Endocrine Society in Endocrinology
- Vol. 152 (1) , 48-58
Adipose Triglyceride Lipase-Null Mice Are Resistant to High-Fat Diet–Induced Insulin Resistance Despite Reduced Energy Expenditure and Ectopic Lipid Accumulation
Adipose triglyceride lipase (ATGL) null (−/−) mice store vast amounts of triacylglycerol in key glucoregulatory tissues yet exhibit enhanced insulin sensitivity and glucose tolerance. The mechanisms underpinning these divergent observations are unknown but may relate to the reduced availability of circulating fatty acids. The aim of this study was to determine whether the enhancements in insulin stimulated glucose metabolism in ATGL−/− mice persist when challenged with a high-fat diet. ATGL−/− mice fed a low-fat diet exhibit improved whole-body insulin sensitivity and glucose tolerance compared with wild-type mice. Wild-type mice became hyperlipidemic and insulin-resistant when challenged with a high-fat diet (HFD, 60% fat) for 4 wk. ATGL−/− mice fed a HFD had elevated circulating fatty acids but had reduced fasting glycemia compared to pre–high-fat diet levels and were refractory to glucose intolerance and insulin resistance. This protection from high-fat diet–induced metabolic perturbations was associated with a preference for fatty acid utilization but reduced energy expenditure and no change in markers of mitochondrial capacity or density. The protection from high-fat diet–induced insulin resistance in ATGL−/− mice was due to increased cardiac and liver insulin-stimulated glucose clearance despite increased lipid content in these tissues. Additionally, there was no difference in skeletal muscle insulin-stimulated glucose disposal, but there was a reduction observed in brown adipose tissue. Overall, these results show that ATGL−/− mice are protected from HFD-induced insulin resistance and reveal a tissue specific disparity between lipid accumulation and insulin sensitivity.
- 15 September 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (1) , 146-156
Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice
Hepatic steatosis is characterised by excessive triacylglycerol accumulation and is strongly associated with insulin resistance. An inability to efficiently mobilise liver triacylglycerol may be a key event mediating hepatic steatosis. Adipose triacylglycerol lipase (ATGL) is a key triacylglycerol lipase in the liver and we hypothesised that liver-specific overproduction of ATGL would reduce steatosis and enhance insulin action in obese rodents.
- 15 September 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (1) , 146-156
Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice
Hepatic steatosis is characterised by excessive triacylglycerol accumulation and is strongly associated with insulin resistance. An inability to efficiently mobilise liver triacylglycerol may be a key event mediating hepatic steatosis. Adipose triacylglycerol lipase (ATGL) is a key triacylglycerol lipase in the liver and we hypothesised that liver-specific overproduction of ATGL would reduce steatosis and enhance insulin action in obese rodents.
- 1 July 2009
- Published by Elsevier in Cell Metabolism
- Vol. 10 (1) , 40-47
Pigment Epithelium-Derived Factor Contributes to Insulin Resistance in Obesity
- 1 July 2009
- Published by Elsevier in Cell Metabolism
- Vol. 10 (1) , 40-47
Pigment Epithelium-Derived Factor Contributes to Insulin Resistance in Obesity